Nicholas Ashton received a PhD from King’s College London in 2017 and joined the group of Henrik Zetterberg at the University of Gothenburg, where he made major developments in the use of novel blood tests for Alzheimer’s disease and related disorders using mass spectrometry and highly sensitive immunoassays. Dr. Ashton is lauded for his leadership skills, internationally recognized for his contributions to the field and appears on Clarivate’s list of the world’s most highly-cited researchers, publishing more than 200 articles by the age of 36. In 2021, he received the Queen Silvia of Sweden Prize for a Young Researcher for his contributions to the dementia field. As the senior director of the biomarker program at the Banner Sun Health Research Institute, he aims to make this the state-of-the-art facility a global leader in high-throughput biomarker measurements and novel discoveries to tackle neurodegenerative disorders.